Management and Outcome of Left Ventricular Assist Device Infections in Patients Undergoing Cardiac Transplantation.

Zerelda Esquer GarrigosNatalia E Castillo AlmeidaPooja GurramPrakhar VijayvargiyaCristina G Corsini CampioliJohn M StulakStacey A RizzaLarry M BaddourM Rizwan Sohail

Published in: Open forum infectious diseases (2020)

Patients with an LVAD-specific infection were treated with 2 weeks of pathogen-directed therapy postheart transplant without any relapses. For those without LVAD-specific infection or uncomplicated LVAD-related bacteremia who had completed antimicrobial therapy pretransplant, antibiotics were discontinued after standard perioperative prophylaxis and no relapses were observed.

Keyphrases

left ventricular assist device
patients undergoing
cell therapy
stem cells
bone marrow
gestational age
smoking cessation